Nogapendekin alfa inbakicept

Phase 3Protein / enzyme

IImmunityBio, Inc.

Nogapendekin alfa inbakicept is one of 77 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaNot yet recruiting

SepsisNot yet recruiting

Myxoid LiposarcomaRecruiting

LymphopeniaActive, not recruiting

Non-Small Cell Lung Cancer Stage IVRecruiting

PneumoniaPhase 3

Not yet recruiting

SepsisPreclinical

Not yet recruiting

Myxoid LiposarcomaPhase 1

Recruiting

LymphopeniaPreclinical

Active, not recruiting

Non-Small Cell Lung Cancer Stage IVPreclinical

Recruiting

Competition

Competitive Landscape

152 competitors in Pneumonia

#DrugCompanyPhaseTrials

Nogapendekin alfa inbakicept

IImmunityBio, Inc.

Phase 3

2 2

Jakafi

Incyte

Preclinical

1 3

Prevacid

Takeda

Preclinical

1 4

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 5

Innohep

Jazz Pharmaceuticals

Preclinical

1 6

Zantac 150

CChattem

Preclinical

2 7

Retrovir

BBp Consulting, Inc

Preclinical

2 8

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Pepcid

KKenvue Brands

Preclinical

1 10

Aciphex

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Pneumonia

NCT07492888

Q3 2028

Phase 2Not yet recruiting

Sepsis

NCT07783789

Q4 2029

Phase 3Not yet recruiting

Pneumonia

NCT07492875

Q1 2032

Phase 1Not yet recruiting

Metastatic Urothelial Carcinoma

NCT07217496

Clinical

Trials by Indication[1]

Pneumonia2 trials

Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07492888·20 enrolled

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Not yet recruiting·IImmunityBio, Inc.·Phase 3·NCT07492875·10 enrolled

Lymphopenia1 trial

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Available·IImmunityBio, Inc.··NCT06956547

Sepsis1 trial

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis

Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07783789·50 enrolled

Metastatic Urothelial Carcinoma1 trial

Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma

Not yet recruiting·VVadim S Koshkin·Phase 1·NCT07217496·18 enrolled

Pancreatic Cancer Resectable1 trial

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Withdrawn·IImmunityBio, Inc.·Phase 1·NCT07488884

2 more indications

Myxoid Liposarcoma1 trial

A Pilot Trial of N-803 in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Recruiting·NNorthwestern University·Phase 1·NCT07261657·8 enrolled

Non-small Cell Lung Cancer Stage IV1 trial

A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

Recruiting·WWashington University School of Medicine·Preclinical·NCT07355205·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Nogapendekin alfa inbakicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nogapendekin alfa inbakicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nogapendekin alfa inbakicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: IImmunityBio, Inc.

Nogapendekin alfa inbakicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2028

Q4 2029

Q1 2032

Trials by Indication[1]

Pneumonia2 trials

Lymphopenia1 trial

Sepsis1 trial

Metastatic Urothelial Carcinoma1 trial

Pancreatic Cancer Resectable1 trial

Myxoid Liposarcoma1 trial

Non-small Cell Lung Cancer Stage IV1 trial

References

Drug Info

Quick Facts

Related News